A Phase II Study of Intermittent Dacomitinib in Patients with Advanced Non-Small Cell Lung Cancer

Full Title
Phase 2 Open Label Trial of Oral Intermittent Dacomitinib in Patients with Advanced NSCLC

Erlotinib is the usual first treatment for patients with non-small cell lung cancers (NSCLC) that have EGFR mutations. The drug often shrinks cancers, but eventually stops working.

Dacomitinib is an investigational drug that targets the same part of the cancer cell as erlotinib. It has been evaluated in several other clinical trials. In this study, researchers want to see if giving a higher dose of dacomitinib less often will be effective for shrinking NSCLC tumors or preventing them from growing. Investigators want to determine if this dosing schedule is safe in patients. Dacomitinib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have NSCLC that has spread to other parts of the body. Most patients enrolled will have EGFR mutations in their lung cancer, but some patients will have other gene changes that make researchers think dacomitinib may be effective in controlling their tumors.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Helena Yu at 646-888-4274.

Lung Cancer, Non-Small Cell